## ACAD: ACADIA Pharmaceuticals Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.8% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($25.44)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026**
- Source: Business Wire | 20251218T210753 | Somewhat-Bullish | Relevance: 100%
- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced it will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, in San Francisco. Catherine Owen Adams, CEO, will represent the company, and a live webcast will be available on acadia.com. The company also highlighted its commitment to neurological and rare disease communities, with FDA-approved treatments for Parkinsonâ€™s disease psychosis and Rett syndrome, and a robust pipeline.

**2. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Rating of "Moderate Buy" by Analysts**
- Source: MarketBeat | 20251218T070953 | Somewhat-Bullish | Relevance: 100%
- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has received a consensus "Moderate Buy" rating from 21 brokerages, with an average 12-month price target of $29.95. The company recently surpassed earnings expectations, reporting an EPS of $0.42 against an estimated $0.14, and revenue of $278.6 million. Despite positive analyst sentiment, insider selling activity was noted, with executives reducing their positions by 14-16%.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | HC Wainwright & | $37 | $32 | +16% |
| 2025-12-11 | Stifel | $25 | $24 | +4% |
| 2025-12-02 | Mizuho | $29 | $24 | +21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | HC Wainwright & | main | Buy |
| 2025-12-11 | Stifel | main | Hold |
| 2025-12-02 | Mizuho | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 3 ($1.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Baker Bros. Advisors: 25.4% (0.0%)
- Blackrock Inc.: 12.0% (-1.9%)
- Vanguard Group Inc: 9.0% (-0.6%)
- State Street Corpora: 4.3% (+17.4%)
- RTW Investments LP: 4.2% (-20.6%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.1% 5d) with bearish MACD, trend may be turning.
2. Elevated short interest (8.2%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 3 raises (avg +14%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Quality metrics strong (ROE 35%, margin 25%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.45). Analyst sentiment positive (3 raises, avg +14%). Insider selling cluster ($1.0M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.6B |
| Beta | 0.67 |
| 52W Range | $13.40 - $27.73 |
| Short Interest | 8.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.42 |
| Forward P/E | 33.7 |
| Current P/E | 33.3 |
| YoY Growth | -1.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 3.9% to 0.8% (-3.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.2pp (needs >3.0% for momentum thesis). MRS_5 (-0.4%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SUH (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.79% (CS: 67) | Neutral |
| RSI_14 | 65.2 | Neutral |
| MACD Histogram | -0.05 | Bearish |
| vs SMA20 | 1.043x | Above |
| vs SMA50 | 1.143x | Above |
| vs SMA200 | 1.265x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $27.16
- **Stop Loss:** $25.44 (6.3% risk)
- **Target:** $28.88 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 697
- **Position Value:** $18,930.52
- **Portfolio %:** 18.93%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-25 (Est: $0.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.15 | $0.42 | +189.0% |
| 2025Q2 | $0.14 | $0.16 | +15.3% |
| 2025Q1 | $0.11 | $0.11 | +4.5% |
| 2024Q4 | $0.22 | $0.86 | +292.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*